Benzinga | Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals

Benzinga - Feed Your Mind.

Market Overview

Tuesday, May 21, 2013

Benzinga's Top Pre-Market Gainers (ACRX, FXEN, JASO, News, SDBT, Pre-Market Outlook, Markets, Movers / Tue, 08:10am)

Thursday, May 02, 2013

AcelRx Pharmaceuticals Presents Positive Clinical Data for the Sufentanil NanoTab PCA System at ASRA Medical Meeting (ACRX, News, FDA / Thu, 07:31am)

Wednesday, April 24, 2013

Top-line Data Show AcelRx Pharmaceuticals' ARX-04 Achieves Primary Endpoint in Dose-Finding Phase 2 Clinical Trial (ACRX, News, FDA / Wed, 07:30am)

Monday, April 08, 2013

UPDATE: Jefferies Initiates AcelRx Pharmaceuticals with Buy on Expected FDA Approval for ARX-01 (ACRX, Analyst Color, Initiation, Analyst Ratings / Mon, 09:43am)
Benzinga's Top Initiations (ACRX, GWW, HPTX, SSNI, Initiation, Analyst Ratings / Mon, 09:01am)

Tuesday, February 19, 2013

AcelRx Pharma Offers Updates on Clinical Trials (ACRX, News / Tue, 08:40am)

Friday, December 14, 2012

AcelRx Pharma Announces Exercise of Option to Buy Additional Shares (ACRX, News, Offerings / Fri, 01:16pm)

Friday, December 07, 2012

Benzinga's Top Pre-Market Gainers (ACRX, CZR, News, SWHC, TLAB, Pre-Market Outlook, Markets, Movers / Fri, 09:10am)
AcelRx Pharmaceuticals Prices 12.5M Share Offering at $3.31/Share (ACRX, News, Guidance, Asset Sales, Management, Global / Fri, 07:33am)

Wednesday, December 05, 2012

A Peek Into The Market Before The Trading Starts (ACRX, ACTG, ADTN, ALV, CTL, DOX, News, Futures, Global, Pre-Market Outlook, Markets / Wed, 08:09am)
AcelRx Pharmaceuticals Announces Proposed 10M Share Secondary Offering (ACRX, News, Guidance, Management / Wed, 07:18am)

Thursday, November 15, 2012

FROM EARLIER: AcelRx Announces Primary Endpoint Met in Phase 3 Non-Inferiority Study of Sublingual Sufentanil NanoTab® PCA System vs. IV PCA Morphine for Post-Operative Pain (ACRX, News, FDA / Thu, 09:28am)

Wednesday, November 14, 2012

AcelRx Announces Phase 3 Comparative Study Involving the Sufentanil NanoTab PCA System Meets Primary End-Point (ACRX, News, Guidance, Asset Sales, Management, Stock Split, M&A, Global / Wed, 11:24pm)

Monday, November 05, 2012

AcelRx Pharmaceuticals Doses the First Subjects in ARX-04 Phase 2 Study (ACRX, News, Guidance, Contracts / Mon, 08:39am)

Wednesday, October 03, 2012

AcelRx Receives Notice of Eligibility for Centralized Review from European Medicines Agency for the Sufentanil NanoTab PCA System (ACRX, News, Guidance, Management, M&A, Global / Wed, 07:41am)

Wednesday, August 29, 2012

AcelRx Pharmaceuticals Receives Fourth and Fifth U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms (ACRX, News / Wed, 07:32am)

Wednesday, August 01, 2012

AcelRx Pharmaceuticals Receives Two Additional U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms (ACRX, News, FDA, Press Releases / Wed, 07:34am)

Wednesday, June 20, 2012

AcelRx Pharmaceuticals Receives First U.S. Patent for Small-Volume Oral Transmucosal Dosage Forms (ACRX, News, FDA / Wed, 07:30am)

Wednesday, May 30, 2012

AcelRx Pharmaceuticals Announces Pricing of a $10.0M PIPE Financing (ACRX, News, Financing / Wed, 07:31am)

Thursday, April 12, 2012

AcelRx Announces Initiation of Second Phase 3 Clinical Trial for ARX-01, the Sufentanil NanoTab PCA System, for the Treatment of Acute Post-Operative Pain (ACRX, News, FDA / Thu, 07:30am)

Thursday, March 08, 2012

Benzinga's Microcap Movers for Wednesday March 7, 2012 (ACRX, Long Ideas, News, SPEX, TBET, Short Ideas, Small Cap, M&A, Global, Trading Ideas / Thu, 08:29am)

Wednesday, March 07, 2012

AcelRx Announces Initiation of Phase 3 Clinical Program for ARX-01, the Sufentanil NanoTab® PCA System for the Treatment of Post-Operative Pain (ACRX, News, FDA / Wed, 08:23am)

Tuesday, January 31, 2012

AcelRx Announces its ARX-01 Phase 3 Program Expected to Start Late Q1 or Early Q2 2012 (ACRX, News, FDA / Tue, 08:31am)

Friday, December 30, 2011

Morning Market Losers (ACRX, BASI, CYTXW, DCTH, News, Movers & Shakers, Intraday Update, Markets / Fri, 11:24am)

Wednesday, September 28, 2011

AcelRx Pharmaceuticals Appoints Mark G. Edwards To Its Board of Directors (ACRX, News, Management / Wed, 07:31am)

Thursday, June 30, 2011

AcelRx Secures $20 Million Loan Financing Agreement, Expected to Extend Its Operating Cash Runway Into 2013 (ACRX, News, Financing / Thu, 01:31pm)

Tuesday, May 31, 2011

AcelRx Announces $5.6 Million Department of Defense Grant to Develop ARX-04 (ACRX, News / Tue, 07:32am)

Tuesday, May 10, 2011

AcelRx European Patent Covering its NanoTab® Sublingual Delivery Technology for Acute and Breakthrough Pain Pipeline Products Emerges From Opposition Period (ACRX, News, FDA / Tue, 07:41am)

Friday, April 01, 2011

Piper Jaffray Overweight On AcelRx Pharmaceuticals (ACRX) (ACRX, Analyst Color, PCA, Price Target, Analyst Ratings / Fri, 07:54am)

Thursday, March 24, 2011

Piper Jaffray Initiates AcelRx Pharmaceuticals At Overweight, $7 PT (ACRX, Price Target, Initiation, Analyst Ratings / Thu, 07:45am)

Benzinga Professional

Brain Trust

Stocks to Watch for the Week of May 20, 2013

InvestorsObserver

MORE FROM InvestorsObserver

Procrastination Nation

MORE FROM Michael Prus

The Next Chapter…

MORE FROM Matt Newman

See All Brain Trust Columnists

stats for benzinga